BioSpace News Archive

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, has voluntarily withdrawn the U.S. COPIKTRA indication for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been terminated.

Xoran Technologies announces that the first VetCAT IQ™ has been installed at an exotics-only animal hospital.

GreenLight Biosciences and IAVI, a nonprofit scientific research organization, announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to 1 employee of non-statutory stock options for the purchase of up to an aggregate of 2,000 shares of Yumanity’s common stock.

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

SINOVAC Biotech Ltd. announced the Company’s subsidiary SINOVAC Biotech Co., Ltd (“SINOVAC Beijing”) settled the litigation with Mr. Aihua Pan concerning its business license and seals.

Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) , announced today that the U.S. Food and Drug Administration (FDA) denied a request from the company to adjust the analysis of the pivotal AGENT study’s secondary endpoint of progression-free survival (PFS).

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for The dividend will be paid on March 8, 2022 , to all stockholders of record as of the close of business on February 15, 2022 . This represents a 10% increase from that paid in each of the prev

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”).